Aug 2026· Journal of Biological Chemistry· Vol 302, pp. 113419· 0 citations· 55 references
Medicine
TL;DR
It is shown that ATR, a key regulator of DNA replication stress, is a novel interacting partner of HBO1, and ATR is discovered as a potential biomarker for WM-3835 treatment.
Abstract
Mounting evidence has shown that histone acetyltransferase binding to ORC1 (HBO1) serves as an oncoprotein, warranting the use of the small molecule inhibitor WM-3835 for cancer therapy. However, HBO1 is ubiquitously expressed in both tumor and normal tissues, with potential to increase the risk of systemic toxicity. This unmet need highlights the importance of identifying suitable biomarkers to predict the sensitivity to HBO1 inhibitor. Here, we show that ATR, a key regulator of DNA replication stress, is a novel interacting partner of HBO1. In addition, we reveal a regulatory function of HBO1 in DNA replication stress responses, in an ATR-dependent manner. Mechanistically, ATR mediated HBO1 Ser50/53 phosphorylation interferes with the genomic binding of HBO1 and regulates gene expression. Notably, overexpression of HBO1 mutated at the ATR phosphorylation site (S50/53A) dampens the expression of DNA repair related genes and suppresses tumor colony formation, consistent with the observations of WM-3835 treatment. Inhibition of ATR significantly antagonized the sensitivity to WM-3835 treatment. Collectively, our findings uncovered a previously unidentified role of HBO1 in the regulation of replication stress and discovered ATR as a potential biomarker for WM-3835 treatment.
Poly (ADP-ribose) polymerase inhibitors (PARPi) have revolutionized the treatment of homologous recombination (HR)-deficient tumors. Nevertheless, their clinical utility is often compromised by the emergence of resistance. Although genetic restoration of HR is a well-established resistance mechanism, emerging evidence...
Woori Bae, Eun A. Ra, Myon Hee Lee· Frontiers in Pharmacology· 0 citations
The hypothesis emphasizes the need to clarify the molecular mechanisms and signaling pathways associated with KAT8–H4K16ac, especially in relation to apoptotic pathways, which could offer new insights and justifications for treatment strategies in cisplatin‐resistant osteosarcoma.
Zhen-Qun Zhao, Guohui Yu, Shi-Kui Wu et al.· Med Research· 0 citations
Bromodomain and extra-terminal (BET) proteins, BRD2, BRD3, BRD4, and BRDT, couple histone acetylation to transcription by recruiting elongation and transcription factor complexes to chromatin. Although BET proteins are promising therapeutic targets, the functions of individual family members remain incompletely underst...
Josefina Mendez, Simone Bruno, Alexandra Indeglia et al.· bioRxiv· 0 citations
Abstract Many cancer cells exhibit elevated replication stress and are highly dependent on ataxia telangiectasia and Rad3-related (ATR) kinase activity to maintain genomic stability and survival. While ATR inhibitors (ATRi) have great promise as therapeutic agents, intrinsic or acquired resistance will likely be a sign...
Samah W. Awwad, Holly Barber, Josie Coulthard et al.· Nucleic Acids Research· 0 citations
Inflammation exerts context-dependent influences on tumor progression and therapeutic response. Although chemotherapy remains a cornerstone of cancer treatment, its functional interplay with inflammatory signaling is still incompletely understood. Here, we identify TANK-binding kinase 1 (TBK1) as a critical modulator o...
Wei Zhou, Xiangyu Wang, Susanne S. Steigleder et al.· Proceedings of the National...· 0 citations
Global upregulation of transcription, or hypertranscription, is observed in most human cancers, driven by the action of oncogene-encoded transcription factors (TFs). TF interactions with RNA Polymerase II (Pol II) are mediated by kinases that phosphorylate the Pol II C-terminal domain (CTD) to drive productive elonga...
S. Henikoff, Robert N. Eisenman, K. Ahmad· Epigenetics & Chromatin· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.